T

    Telomir Pharmaceuticals, Inc. Common Stock (TELO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.05 (-4.20%)

    Market Cap: $78.40M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(2/4)
    Avg Surprise
    -31.34%
    Streak
    1 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.79N/AN/ABeat-364.7%
    Mar 26
    		$-0.03N/AN/ABeat+58.9%
    Dec 25
    		$-0.06N/AN/ABeat+40.0%
    Sep 25
    		$-0.03N/A+57.14%Beat+85.2%
    Jun 25
    		$-0.17$-0.08-112.50%Miss-247.6%
    Mar 25
    		$-0.07$-0.10+30.00%Beat+68.9%
    Dec 24
    		$-0.10$-0.05-100.00%Miss-
    Sep 24
    		$-0.20N/AN/ABeat-
    Jun 24
    		$-0.05N/AN/ABeat-
    Mar 24
    		$-0.23N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.25EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-213.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-1391.77x
    Current Ratio16.14xQuick Ratio16.14x
    Trading Statistics
    Beta-0.24Avg Volume55.01K
    52-Week High$2.0952-Week Low$0.89

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.14
    SMA 20$1.14
    SMA 50$1.19
    SMA 200$1.28
    EMA 10$1.15
    EMA 20$1.15
    EMA 50$1.18
    EMA 200$1.37

    MACD

    Line: -0.01Signal: -0.01Hist: 0.01

    ADX

    ADX: 13.4+DI: 18.7-DI: 16.9

    Aroon & PSAR

    Aroon Up28.0
    Aroon Down68.0
    PSAR$1.04

    Bollinger Bands

    Upper Band$1.24
    Lower Band$1.05
    %B Position1650%(Upper)
    Band Width0.48

    RSI (14-Day)

    Neutral
    48.2

    Momentum Oscillators

    Stoch %K80.3
    Stoch %D83.4
    Williams %R-35.5
    ROC (10d)4.6%
    Momentum0.05
    CCI (20d)26.9
    MFI (14d)48.3

    Volatility Measures

    ATR (14d)$0.07(6.0%)
    StdDev (20d)0.05
    Hist Vol57.8%(High)

    Volume Flow

    VWAP$1.16
    OBV182.2M
    AD Line-121.8M
    CMF (20d)-0.022

    Volume Metrics

    Avg Vol (20d)54.9K
    Vol Ratio0.7x
    VWMA (20d)$1.15

    Pivot Points

    R3$1.27
    R2$1.23
    R1$1.21
    Pivot Point$1.18
    S1$1.16
    S2$1.12
    S3$1.10

    Advanced Oscillators

    TSI-2.21
    Ultimate Osc45.4
    KST-42.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$18.79M$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/A$9.40M$6.01M$1.47M$1.92MN/AN/A
    Gross ProfitN/AN/AN/AN/AN/AN/A$9.40M$-6,006,178$-1,474,496$-1,916,064N/AN/A
    Operating Expenses$1.76M$1.04M$2.13M$1.15M$5.07M$2.19M$2.91M$6.01M$1.47M$1.92M$1.08M$954,153
    R&D$444,674$467,797$1.30M$759,525$42,839$336,996$269,083$627,434$594,801$804,023$203,784$262,562
    SG&A$1.32M$573,539$838,472$386,951$5.03M$1.85M$2.64M$5.38M$879,695$741,541$395,290$102,191
    Operating Income$-1,764,676$-1,041,336$-2,134,681$-1,146,476$-5,069,910$-2,187,782$-2,905,435$-6,006,178$-1,474,496$-1,916,064$-1,078,624$-954,153
    Interest Income$0$51,644$72,100$44,182$1,362$8,000$7,061$15,445$25,493$0$0$0
    Interest Expense$3,028$1,255$1,388$2,730$1,342$7,954$1$0$0$4.34M$761,824$757,173
    Income Before Tax$-1,721,528$-990,947$-2,061,193$-1,102,294$-5,069,890$-2,179,828$-2,898,373$-5,990,733$-1,449,003$-6,254,607$-9,327,215$-1,711,326
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-1,916,064$-1,078,624$-954,153
    Net Income$-1,721,528$-990,947$-2,061,193$-1,102,294$-5,069,890$-2,179,828$-2,898,373$-5,990,733$-1,449,003$-6,254,607$-9,327,215$-1,711,326
    EBITDA$-1,718,500$-989,692$-2,062,581$-1,099,564$-5,068,548$-2,179,828$-2,898,374$-5,990,733$-1,423,510$-1,916,064$-8,565,391$-954,153
    EBITN/AN/AN/AN/A$-5,069,910$-2,188,000$-941,374$-5,990,733$-1,449,003$-3,832,128$-8,565,391$-1,908,306
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TELO

    News

    Telomir Pharmaceuticals (TELO): John Paul DeJoria reports 5.169% ownership stake

    John Paul DeJoria has filed an amended beneficial ownership report for Telomir Pharmaceuticals (TELO), disclosing a 5.169% ownership stake. This represents 3,554,871 shares of common stock, with DeJoria holding sole voting and dispositive power over these shares. The reported ownership is based on 68,774,956 shares outstanding as of August 13, 2026.

    Stock Titan•8/15/26•
    Neutral

    Telomir Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez

    This article is a filing document from Telomir Pharmaceuticals, specifically a Statement of changes in beneficial ownership of securities. It concerns Officer Aminov Erez and details modifications to their security holdings within the company.

    Moomoo•8/5/26•
    Neutral

    Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis

    This article analyzes the valuation of Telomir Pharmaceuticals Inc (TELO), highlighting its current valuation score of 6.89, which ranks 142 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -4.39, indicating it is significantly below its recent high and above its recent low. The article notes that relevant P/B data has not yet been disclosed by the company.

    TradingKey•7/31/26•
    Somewhat-Bearish

    TELO|Telomir Pharmaceuticals Inc|Price:1.245|Chg%:+0.035

    Telomir Pharmaceuticals Inc (TELO) has healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. Institutional ownership is notably high, and analysts have set a high price target. The company focuses on developing Telomir-1, a novel small molecule designed to lengthen telomeres and combat age-related conditions.

    TradingKey•7/30/26•
    Neutral

    Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis

    This article provides a detailed financial overview and news analysis for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), including its current stock price, key financials, income statements, balance sheets, cash flow, and peer comparison. It also offers a company profile highlighting its focus on developing therapeutic treatments for age-related inflammatory conditions. The data indicates the company is in a preclinical stage with negative net income and total revenue of $0.00000M across reported years.

    Kalkine•7/28/26•
    Neutral

    Frequently Asked Questions About TELO

    Does TELO pay dividends?
    Telomir Pharmaceuticals, Inc. Common Stock (TELO) does not currently pay a regular dividend.
    What is TELO's market cap?
    Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a market capitalization of $78.40M with a current stock price of $1.14.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In